Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically…
Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts),…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced…
LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The…